Cel sci Corporation  (CVM)
Other Ticker:  
Price: $1.4700 $-0.04 -2.649%
Day's High: $1.53 Week Perf: -2 %
Day's Low: $ 1.44 30 Day Perf: -25.76 %
Volume (M): 186 52 Wk High: $ 3.23
Volume (M$): $ 273 52 Wk Avg: $2.06
Open: $1.51 52 Wk Low: $1.04

 Market Capitalization (Millions $) 71
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Cel Sci Corporation
Cel-Sci Corporation is a biotechnology company that focuses on the development of immunotherapy treatments for cancer and other diseases. The company's lead product, Multikine, is a potential immunotherapy treatment for head and neck cancer that is currently in late-stage clinical trials. Cel-Sci also has a platform technology called L.E.A.P.S. (Ligand Epitope Antigen Presentation System) that allows for the development of targeted immunotherapies for a variety of diseases. The company is headquartered in Vienna, Virginia, and is traded on the NYSE American exchange under the ticker symbol CVM.

   Company Address: 8229 Boone Boulevard Vienna 22182 VA
   Company Phone Number: 506-9460   Stock Exchange / Ticker: NYSEAMER CVM


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cel Sci Corporation

Cel Sci Corporation's Revolutionary Discovery Shakes Stock Market Amidst First Quarter Losses in 2024

Investors are always on the lookout for potential growth opportunities and developments in the stock market. A recent earnings cycle from October to December 2023 has shed light on some interesting facts about a company's financial performance. While stockholders had not anticipated any major changes, the company managed to operate more cost-effectively, significantly reducing its operating loss and improving its overall deficit.
Evolving Business demonstrates increased efficiency:
One of the key highlights of this earnings cycle is the company's ability to operate much more efficiently compared to the previous year. In the same period, the company recorded an operating loss of $-6.485887 million, a significant improvement from the previous year's figure of $-7.650549 million. This data showcases the evolving business's capacity to manage costs and optimize operations, leading to a reduction in losses.

Cel Sci Corporation

Cel Sci Corporation's Financials Raise Concerns as Expenses Surge in Fiscal Fourth Quarter of 2023

The Biotechnology & Pharmaceuticals industry has been closely observed during the July to September reporting cycle, with many companies disclosing their financial results. One such company is Cel Sci Corporation, which recently reported an operating shortfall of $-7.467522 million for the financial period ending Sep 30, 2023. Although the results may seem discouraging at first glance, a comprehensive analysis reveals a more bullish outlook for the company.
Operating Surplus Comparison:
Comparing the operating surplus of the fourth quarter of 2022 with the same period in 2023, the difference is striking. In 2022, Cel Sci Corporation achieved a commendable operating surplus of $18.290441 million. However, in the fiscal fourth quarter of 2023, the company faced challenges and reported a net loss of $-7.631 million in contrast.

Cel Sci Corporation

Cel Sci Corporation Shows Promising Improvement in Financial Performance, Drastically Reducing Operating Losses in Q3 2023

Following the earnings reports of various businesses in the Biotechnology & Pharmaceuticals industry, some lesser-known companies are starting to gain attention. One such company is Cel Sci Corporation (CVM), which recently revealed a significant improvement in its operating loss for the third quarter of 2023. The company reported a loss of $-8.181757 million, compared to a loss of $-27.114625 million in the same three-month period the previous year.
This improvement in operating loss suggests that Cel Sci Corporation has become more cost-effective in its operations, which is an encouraging sign for investors. The company has managed to reduce its losses to $-8.367 million during the third quarter of 2023. This positive outcome indicates that Cel Sci Corporation is making strides towards financial stability and profitability.

Cel Sci Corporation

Cel Sci Corporation's Operating Deficit Improves to $-18.4 Million in Q2 2023, Indicating Potential Growth Amidst Biotech & Pharma Industry

Investing in the stock market can be a daunting endeavor, but keeping an eye on industry leaders can help guide you in making well-informed decisions. One such company to consider is Cel Sci Corporation, an esteemed Biotechnology & Pharmaceuticals enterprise. While they have recorded a cumulative net loss of $-27 million during the 12 months ending in the second quarter of 2023, analysts predict future growth for this corporation.
Despite experiencing a negative return on equity (ROE) of -90.48%, it is essential to note that 110 other companies within the Biotechnology & Pharmaceuticals industry recorded a higher ROE. In the total ranking, Cel Sci Corporation's ROE has dropped compared to the first quarter of 2023 from 0 to 2511, which is not ideal, but it is not altogether detrimental either. Biotechnology & Pharmaceuticals industry experts continue to scrutinize the second quarter of 2023, but the present operating deficit of $-8.176246 million gives cause for optimism.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com